A plee for wider open inovation in drug delivery

1. Open Innovation in the Inhalation Field:
Academia and Industry as Partners
Philippe G Rogueda
December 2008

2. DDL 19
Open innovation in action in the inhalation field
Industry Academia
- Physical chemistry of non-aqueous systems
- Phase diagrams of excipients in HFA
- AFM applied to pharmaceutical powders
- CAB model
- AFM under pressure
- Design of an AFM pressure cell
- Pressurised HRUS
- Aerosolisation models
- Propellant handling technologies
- Powder processing technologies
- Inhaler performance knowledge
- Trouble shooting of technologies
Tools – Knowledge - Inventions

3. DDL 19
Example 1: Atomic Force Microscopy
Pressure Cell
Text
CAB
AFM
Standard Cell

4. DDL 19
Example 2: Non-aqueous colloid science
Non-Aqueous Colloids
Halogen Bond Phase Diagrams
Interactions in
Non-Aqueous Liquids

5. DDL 19
Example 3: pMDI formulating
Tools and Knowledge:
Sample preparation tools
 Solubility measurements
Turbiscan tools and measurements

6. DDL 19
What is open innovation ?
“Open innovation is the use of purposive inflows and outflows of
knowledge to accelerate internal innovation, and expand the markets
for external use of innovation, respectively. [This paradigm] assumes
that firms can and should use external ideas as well as internal ideas,
and internal and external paths to market, as they look to advance
their technology”
Henry Chesbrough
Open Innovation: Researching a New Paradigm
Harvard Business School Press 2003

7. DDL 19
Open Innovation Mindset
Closed innovation Principles Open innovation Principles
The smart people in our field work for us. Not all the smart people work for us. We
need to work with smart people inside
and outside our company.
To profit from research and development External R&D can create significant value;
(R&D), we must discover it, develop it and internal R&D is needed to claim some
ship it ourselves portion of that value.
If we discover it ourselves, we will get it to We don't have to originate the research to
market first. profit from it.
The company that gets an innovation to Building a better business model is better
market first will win. than getting to market first.
If we create the most and the best ideas in If we make the best use of internal and
the industry, we will win. external ideas, we will win.
We should control our innovation process, so We should profit from others' use of our
that our competitors don't profit from our innovation process, and we should buy
ideas. others' intellectual property (IP) whenever
it advances our own business model.

8. DDL 19
The limits of open innovation
Willingness to share innovation
 Complacency, we know best
Lack of clarity on academia business model
For whose benefit is academic innovation?

9. DDL 19
Changes needed
Clarify academic business model
Aim for realistic I.P. generation
Industry ready to share ancillary technologies

10. DDL 19
The wall Street Journal - 11 Sept 2008
Alicia Mundy
Is open innovation doomed?
Major universities are reviewing the way they handle
funding from drug companies in the wake of criticism
from Sen. Chuck Grassley, who is pressing the federal
agency that controls government health-research money
to get tougher on universities that don't disclose ties to
the industry.